When BioInnovation Institute (BII) started six years ago, their focus was almost exclusively on life science. Now, they fund a much broader range of research-based companies, including quantum technology, AI, biosolutions and other deep tech.
CEO Jens Nielsen sees a larger shift in the landscape: some of the most important future technologies are emerging at the intersection of disciplines, with enabling technologies like quantum and AI increasingly creating new opportunities in areas like life science and biotech.